Cellular Reprogramming to Model and Study Epigenetic Alterations in Cancer

Overview

Journal Stem Cell Res

Publisher Elsevier

Specialty Cell Biology

Date 2020 Nov 17

PMID 33202305

Citations 7

Authors

Jungsun Kim

Affiliations

Soon will be listed here.

Abstract

Although genetic mutations are required for cancer development, reversible non-genetic alterations also play a pivotal role in cancer progression. Failure of well-orchestrated gene regulation by chromatin states and master transcription factors can be one such non-genetic etiology for cancer development. Master transcription factor-mediated cellular reprogramming of human cancer cells allows us to model cancer progression. Here I cover the history and recent advances in reprogramming cancer cells, followed by lessons from cellular reprogramming of normal cells that may apply to cancer. Lastly, I share my perspective on cellular reprogramming for studying epigenetic alterations that have occurred in tumorigenesis, discuss the current limitations, and propose ways to overcome the obstacles in the reprogramming of cancer.

Citing Articles

Inhibition of lung tumorigenesis by transient reprogramming in cancer cells.

Pedrosa P, Zhang Z, Nunez-Quintela V, Macias D, Ge J, Denholm M Cell Death Dis. 2024; 15(11):857.

PMID: 39587064 PMC: 11589828. DOI: 10.1038/s41419-024-07207-2.

From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.

Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins.

Maksimova V, Popova V, Prus A, Lylova E, Usalka O, Sagitova G Int J Mol Sci. 2023; 24(16).

PMID: 37629054 PMC: 10454690. DOI: 10.3390/ijms241612874.

Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.

Eades W, Liu W, Shen Y, Shi Z, Yan B Curr Drug Metab. 2022; 23(12):1000-1010.

PMID: 36515038 PMC: 10258227. DOI: 10.2174/1389200224666221212143904.

An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool.

Javaid N, Choi S Stem Cells Int. 2022; 2022:4537335.

PMID: 36187228 PMC: 9522500. DOI: 10.1155/2022/4537335.

References

Suknuntha K, Ishii Y, Tao L, Hu K, McIntosh B, Yang D . Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. Stem Cell Res. 2015; 15(3):678-693. PMC: 5003778. DOI: 10.1016/j.scr.2015.10.015. View

Lee T, Jenner R, Boyer L, Guenther M, Levine S, Kumar R . Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006; 125(2):301-13. PMC: 3773330. DOI: 10.1016/j.cell.2006.02.043. View

Braun A . A DEMONSTRATION OF THE RECOVERY OF THE CROWN-GALL TUMOR CELL WITH THE USE OF COMPLEX TUMORS OF SINGLE-CELL ORIGIN. Proc Natl Acad Sci U S A. 1959; 45(7):932-8. PMC: 222668. DOI: 10.1073/pnas.45.7.932. View

Lee D, Su J, Kim H, Chang B, Papatsenko D, Zhao R . Modeling familial cancer with induced pluripotent stem cells. Cell. 2015; 161(2):240-54. PMC: 4397979. DOI: 10.1016/j.cell.2015.02.045. View

Buganim Y, Faddah D, Cheng A, Itskovich E, Markoulaki S, Ganz K . Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell. 2012; 150(6):1209-22. PMC: 3457656. DOI: 10.1016/j.cell.2012.08.023. View

Zhao H, Davies T, Ning J, Chang Y, Sachamitr P, Sattler S . A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors. Cell Reprogram. 2014; 17(1):7-18. PMC: 4312798. DOI: 10.1089/cell.2014.0046. View

Li R, Liang J, Ni S, Zhou T, Qing X, Li H . A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010; 7(1):51-63. DOI: 10.1016/j.stem.2010.04.014. View

Hussein S, Puri M, Tonge P, Benevento M, Corso A, Clancy J . Genome-wide characterization of the routes to pluripotency. Nature. 2014; 516(7530):198-206. DOI: 10.1038/nature14046. View

Sakatani T, Kaneda A, Iacobuzio-Donahue C, Carter M, de Boom Witzel S, Okano H . Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 2005; 307(5717):1976-8. DOI: 10.1126/science.1108080. View

10.

Kotini A, Chang C, Chow A, Yuan H, Ho T, Wang T . Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. 2017; 20(3):315-328.e7. PMC: 5337161. DOI: 10.1016/j.stem.2017.01.009. View

11.

Munoz-Lopez A, Romero-Moya D, Prieto C, Ramos-Mejia V, Agraz-Doblas A, Varela I . Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. Stem Cell Reports. 2016; 7(4):602-618. PMC: 5063541. DOI: 10.1016/j.stemcr.2016.08.013. View

12.

Baylin S, Jones P . Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016; 8(9). PMC: 5008069. DOI: 10.1101/cshperspect.a019505. View

13.

Schiebinger G, Shu J, Tabaka M, Cleary B, Subramanian V, Solomon A . Optimal-Transport Analysis of Single-Cell Gene Expression Identifies Developmental Trajectories in Reprogramming. Cell. 2019; 176(6):1517. PMC: 6615720. DOI: 10.1016/j.cell.2019.02.026. View

14.

Folmes C, Nelson T, Martinez-Fernandez A, Arrell D, Lindor J, Dzeja P . Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 2011; 14(2):264-71. PMC: 3156138. DOI: 10.1016/j.cmet.2011.06.011. View

15.

Harris H . The analysis of malignancy by cell fusion: the position in 1988. Cancer Res. 1988; 48(12):3302-6. View

16.

Gandre-Babbe S, Paluru P, Aribeana C, Chou S, Bresolin S, Lu L . Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood. 2013; 121(24):4925-9. PMC: 3682343. DOI: 10.1182/blood-2013-01-478412. View

17.

Bernhardt M, Novak D, Assenov Y, Orouji E, Knappe N, Weina K . Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. Stem Cell Reports. 2017; 8(5):1379-1391. PMC: 5425615. DOI: 10.1016/j.stemcr.2017.03.007. View

18.

Kim J, Bamlet W, Oberg A, Chaffee K, Donahue G, Cao X . Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017; 9(398). PMC: 5727893. DOI: 10.1126/scitranslmed.aah5583. View

19.

MCKINNELL R, Deggins B, Labat D . Transplantation of pluripotential nuclei from triploid frog tumors. Science. 1969; 165(3891):394-6. DOI: 10.1126/science.165.3891.394. View

20.

Kim J, Hoffman J, Alpaugh R, Rhim A, Rhimm A, Reichert M . An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 2013; 3(6):2088-99. PMC: 3726210. DOI: 10.1016/j.celrep.2013.05.036. View